|
1
|
Prat A, Parker JS, Karginova O, Fan C,
Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and
molecular characterization of the claudin-low intrinsic subtype of
breast cancer. Breast Cancer Res. 12:R682010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Perou CM: Molecular stratification of
triple-negative breast cancers. Oncologist. 16:(Suppl 1). S61–S70.
2011. View Article : Google Scholar
|
|
3
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lehmann BD, Bauer JA, Schafer JM,
Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H,
Arteaga CL, et al: PIK3CA mutations in androgen receptor-positive
triple negative breast cancer confer sensitivity to the combination
of PI3K and androgen receptor inhibitors. Breast Cancer Res.
16:4062014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kashiwagi S, Yashiro M, Takashima T,
Nomura S, Noda S, Kawajiri H, Ishikawa T, Wakasa K and Hirakawa K:
Significance of E-cadherin expression in triple-negative breast
cancer. Br J Cancer. 103:249–255. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ricciardi GR, Adamo B, Ieni A, Licata L,
Cardia R, Ferraro G, Franchina T, Tuccari G and Adamo V:
Correction: Androgen receptor (AR), E-Cadherin, and Ki-67 as
emerging targets and novel prognostic markers in triple-negative
breast cancer (TNBC) patients. PLoS One. 10:e01326472015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Safarpour D and Tavassoli FA: A targetable
androgen receptor-positive breast cancer subtype hidden among the
triple-negative cancers. Arch Pathol Lab Med. 139:612–617. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abd-Elazeem MA and Abd-Elazeem MA: Claudin
4 expression in triple-negative breast cancer: Correlation with
androgen receptors and Ki-67 expression. Ann Diagn Pathol.
19:37–42. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Caselitz J, Jaup T and Seifert G:
Lactoferrin and lysozyme in carcinomas of the parotid gland. A
comparative immunocytochemical study with the occurrence in normal
and inflamed tissue. Virchows Arch A Pathol Anat Histol. 394:61–73.
1981. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tuccari G and Barresi G:
Immunohistochemical demonstration of lactoferrin in follicular
adenomas and thyroid carcinomas. Virchows Arch A Pathol Anat
Histopathol. 406:67–74. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cabaret V, Vilain MO, Delobelle-Deroide A
and Vanseymortier L: Immunohistochemical demonstration of
ceruloplasmin and lactoferrin in a series of 59 thyroid tumors. Ann
Pathol. 12:347–352. 1992.(In French). PubMed/NCBI
|
|
12
|
Tuccari G, Giuffrè G, Crisafulli C and
Barresi G: Immuno-histochemical detection of lactoferrin in human
astrocytomas and multiforme glioblastomas. Eur J Histochem.
43:317–322. 1999.PubMed/NCBI
|
|
13
|
Zhou Y, Zeng Z, Zhang W, Xiong W, Wu M,
Tan Y, Yi W, Xiao L, Li X, Huang C, et al: Lactotransferrin: A
candidate tumor suppressor-Deficient expression in human
nasopharyngeal carcinoma and inhibition of NPC cell proliferation
by modulating the mitogen-activated protein kinase pathway. Int J
Cancer. 123:2065–2072. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tuccari G, Barresi G, Arena F and
Inferrera C: Immuno-cytochemical detection of lactoferrin in human
gastric carcinomas and adenomas. Arch Pathol Lab Med. 113:912–915.
1989.PubMed/NCBI
|
|
15
|
Walmer DK, Padin CJ, Wrona MA, Healy BE,
Bentley RC, Tsao MS, Kohler MF, McLachlan JA and Gray KD: Malignant
transformation of the human endometrium is associated with
overexpression of lactoferrin messenger RNA and protein. Cancer
Res. 55:1168–1175. 1995.PubMed/NCBI
|
|
16
|
Farley J, Loup D, Nelson M, Mitchell A,
Esplund G, Macri C, Harrison C and Gray K: Neoplastic
transformation of the endocervix associated with downregulation of
lactoferrin expression. Mol Carcinog. 20:240–250. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Giuffrè G, Arena F, Scarfì R, Simone A,
Todaro P and Tuccari G: Lactoferrin immunoexpression in endometrial
carcinomas: Relationships with sex steroid hormone receptors (ER
and PR), proliferation indices (Ki-67 and AgNOR) and survival.
Oncol Rep. 16:257–263. 2006.PubMed/NCBI
|
|
18
|
Giuffrè G, Barresi V, Skliros C, Barresi G
and Tuccari G: Immunoexpression of lactoferrin in human sporadic
renal cell carcinomas. Oncol Rep. 17:1021–1026. 2007.PubMed/NCBI
|
|
19
|
Tuccari G, Giuffrè G, Scarfì R, Simone A,
Todaro P and Barresi G: Immunolocalization of lactoferrin in
surgically resected pigmented skin lesions. Eur J Histochem.
49:33–38. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ieni A, Barresi V, Grosso M, Rosa MA and
Tuccari G: Immuno-localization of lactoferrin in cartilage-forming
neoplasms. J Orthop Sci. 14:732–737. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ieni A, Barresi V, Grosso M, Rosa MA and
Tuccari G: Lactoferrin immuno-expression in human normal and
neoplastic bone tissue. J Bone Miner Metab. 27:364–371. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ieni A, Barresi V, Branca G, Giuffrè G,
Rosa MA and Tuccari G: Immunoexpression of lactoferrin in bone
metastases and corresponding primary carcinomas. Oncol Lett.
5:1536–1540. 2013.PubMed/NCBI
|
|
23
|
Charpin C, Lachard A, Pourreau-Schneider
N, Jacquemier J, Lavaut MN, Andonian C, Martin PM and Toga M:
Localization of lactoferrin and nonspecific cross-reacting antigen
in human breast carcinomas. An immunohistochemical study using the
avidin-biotinperoxidase complex method. Cancer. 55:2612–2617. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ha NH, Nair VS, Reddy DN, Mudvari P,
Ohshiro K, Ghanta KS, Pakala SB, Li DQ, Costa L, Lipton A, et al:
Lactoferrin endothelin-1 axis contributes to the development and
invasiveness of triple-negative breast cancer phenotypes. Cancer
Res. 71:7259–7269. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tuccari G and Barresi G: Lactoferrin in
human tumours: Immunohistochemical investigations during more than
25 years. Biometals. 24:775–784. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Penco S, Caligo MA, Cipollini G,
Bevilacqua G and Garré C: Lactoferrin expression in human breast
cancer. Cancer Biochem Biophys. 17:163–178. 1999.PubMed/NCBI
|
|
27
|
Benaïssa M, Peyrat JP, Hornez L, Mariller
C, Mazurier J and Pierce A: Expression and prognostic value of
lactoferrin mRNA isoforms in human breast cancer. Int J Cancer.
114:299–306. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ieni A and Tuccari G: Comments on the
‘Prognostic impact and clinicopathological correlation of CD133 and
ALDH1 expression in invasive breast cancer’. J Breast Cancer.
19:96–98. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ieni A, Barresi V, Branca G, Giuffrè G,
Rosa MA and Tuccari G: Immunohistochemical Investigation of
lactoferrin in human bone primary and metastatic tumours. Int J Lab
Med Res. 1:IJLMR-105.
|
|
30
|
Ieni A, Giuffrè G, Lanzafame S, Nuciforo
G, Curduman M, Villari L, Roz E, Certo G, Cabibi D, Salomone E, et
al: Morphological and biomolecular characteristics of
subcentimetric invasive breast carcinomas in Sicily: A multicentre
retrospective study in relation to trastuzumab treatment. Oncol
Lett. 3:141–146. 2012.PubMed/NCBI
|
|
31
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thürlimann B and Senn HJ: Panel members:
Personalizing the treatment of women with early breast cancer:
Highlights of the St Gallen international expert consensus on the
primary therapy of early breast cancer 2013. Ann Oncol.
24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ieni A, Barresi V, Ricciardi GR, Adamo B,
Adamo V and Tuccari G: Prognostic value of androgen receptor
expression in triple negative breast carcinomas: Personal
experience and comments on a review about ‘Triple-negative breast
cancer: Treatment challenges and solutions’ by Collignon et
al. Breast Cancer (Dove Med Press). 8:157–159. 2016.PubMed/NCBI
|
|
33
|
Rakha EA, El-Sayed ME, Green AR, Lee AH,
Robertson JF and Ellis IO: Prognostic markers in triple-negative
breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
|
